Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2018 08:00 ET | Source: INmune Bio, Inc.

INmune Bio Granted Phase I Clinical Trial Authorization of Lead Product INKmune™ in Refractory and Recurrent Ovarian Cancer Patients

LA JOLLA, California, Dec. 19, 2018 (GLOBE NEWSWIRE) -- INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, announced today that...